Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance RADNOR, PA — November 6, 2024-- Certara, Inc. （纳斯达克股票代码：CERT),…
Danielle Pillsbury2024 年 11 月 6 日
How Modeling Was Used to Support the FDA Approval of a Topical Generic Drug Product
Establishing bioequivalence for topical drug products can be challenging and costly, often requiring extensive comparative…
Danielle Pillsbury2024 年 11 月 5 日
Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a recombinant human monoclonal antibody
The article titled "Informing pregnancy dose via target-mediated drug disposition modeling and simulations for a…
Danielle Pillsbury2024 年 11 月 4 日
FAQs on Developing EMA Policy 0070 Submissions
In September 2023, the European Medicines Agency (EMA) reinstated its Policy 0070 requirement to publish…
Jim Gallagher2024 年 11 月 1 日
Improved Translation of Clinical TCE Dosing with Mechanistic Modeling
摘要：Regulatory agencies recommend quantitative justifications for clinical dose selection. T-cell engagers (TCE) pose particular…
Renee Fisher2024 年 10 月 31 日
Applications of a QSP Model of LNP mRNA Delivery for the Treatment of Crigler-Najjar Syndrome Type 1
摘要：Crigler-Najjar syndrome type 1 (CN1) is an autosomal recessive disease caused by a marked…
Renee Fisher2024 年 10 月 31 日
Guiding Target and Lead Optimization for a Molecular Glue Degrader
Learn how to optimize drug properties for protein degrader therapeutics by exploring system characteristics.
Renee Fisher2024 年 10 月 31 日
